Open Access Open Access  Restricted Access Subscription Access

A Required Parameters of the Colestipol that is a Bile Acid Sequestrants Include Usage of the Drug, Other Uses, Special Precautions & Diet, Side Effects and Storage as well as Disposal

Muralinath E., Madhavi Latha C., Ramadevi Ch., Sheethal U., Guruprasad M., Karthik Jayanth Y., Renuka U., Sony Sharlet E.

Abstract


Colestipol is used to reduce the amount of cholesterol (a fat-like substance that can build up in blood vessels leading to heart attack or strokes or other medical conditions). Colestipol is in a class of medications termed as bile acid sequestrate. It demonstrates its activity by binding bile acids in your intestines to form a product that is eliminated from the body.


Full Text:

PDF

References


Buchman, C. R. (2022). Bile acid sequestrants. In Medications for the treatment of diabetes mellitus (p. 250).

Ast, M., & Frishman, W. H. (1990). Bile acid sequestrants. The Journal of Clinical Pharmacology, 30(2), 99–106. https://doi.org/10.1002/j.1552-4604.1990.tb03455.x

U.S. Food and Drug Administration. (n.d.). Cholestyramine powder for suspension: Prescribing information. https://www.accessdata.fda.gov/

King, D. S., Kelley, K. W., Rogers, H. E., & Harrell, K. T. (2001). Cholesterol lowering in the inpatient and outpatient setting. Hospital Pharmacist Report, 15(5), 40–40.

Edmondson, S. D., Burnett, D. A., & Davis, H. R., Jr. (2003). Atherosclerosis: Cholesterol management. In Burger's medicinal chemistry and drug discovery (6th ed., pp. 1–36). John Wiley & Sons.

Bilheimer, D. W. (1991). Clinical considerations regarding treatment of hypercholesterolemia in the elderly. Atherosclerosis, 91(Suppl.), S35–S57. https://doi.org/10.1016/0021-9150(91)90230-Q

U.S. Food and Drug Administration. (n.d.). Cholestyramine for oral suspension: Clinical pharmacology and inactive ingredients. https://www.accessdata.fda.gov/

Marquis, J. K., Dagher, R., & Jones, M. R. (2004). Dietary administration of colesevelam hydrochloride does not affect fertility or reproductive performance in rats. International Journal of Toxicology, 23(6), 357–367. https://doi.org/10.1080/10915810490896418

Chitturi, S., & Farrell, G. C. (2011). Drug-induced liver disease. In E. R. Schiff, M. F. Sorrell, & W. C. Maddrey (Eds.), Schiff's diseases of the liver (10th ed., pp. 703–783). Wiley-Blackwell.

Papazafiropoulou, A. K., Kardara, M. S., & Pappas, S. I. (2012). Dyslipidemia: Causes, diagnosis and treatment. In Dyslipidemia: Causes, diagnosis and treatment (p. 35).


Refbacks

  • There are currently no refbacks.